Table 2 Most frequent potentially inappropriate prescribing events according to START, STOPP and/or Beers criteria
Therapeutic class/medication ± disease | Prevalence % (n) | |
|---|---|---|
Under prescribing according to START | ||
Aspirin or clopidogrel with a documented history of atherosclerotic coronary, cerebral or peripheral vascular disease in patients with sinus rhythm | 15,0 (85) | |
Calcium and vitamin D supplement in patients in the presence of known osteoporosis | 13,9 (79) | |
ACE inhibitor in the presence of chronic heart failure | 12,7 (72) | |
Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, where the patient’s functional status remains independent for activities of daily living and life expectancy is greater than 5 years | 9,5 (54) | |
Antiplatelet therapy in diabetes mellitus with coexisting major cardiovascular risk factors (hypertension, hypercholesterolemia, smoking history) | 9,5 (54) | |
Over/misprescribing according to STOPP or/and Beers | ||
STOPP and Beers | Aspirin for primary cardiovascular preventiona | 16,9 (96) |
Beers | Nonbenzodiazepine (“Z”) hypnotics (i.e., eszoplicone, zaleplon, zolpidem) | 6,2 (35) |
STOPP | Any duplicate drug class prescription | 6,2 (35) |
Beers | Benzodiazepines in the presence of dementia and cognitive impairment | 5,8 (33) |
STOPP and Beers | Long-acting benzodiazepines | 4,9 (28) |
STOPP | Aspirin at dose > 150 mg/day | 4,4 (25) |
STOPP | NSAIDs with moderate to severe hypertension | 3,7 (21) |
Beers | Tertiary TCAs, alone or in combination | 2,6 (15) |